Drug Profile
Evorpacept - ALX Oncology
Alternative Names: ALX-148; CD47/SIRPa-blocking Agent ALX 148; SIRPa Variant ALX 148Latest Information Update: 16 Apr 2024
Price :
$50
*
At a glance
- Originator Alexo Therapeutics
- Developer ALX Oncology; Eli Lilly and Company; Merck & Co; Merck Sharp & Dohme; Quantum Leap Healthcare Collaborative; Zymeworks
- Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Proteins; Recombinant fusion proteins
- Mechanism of Action CD47 antigen inhibitors; Cytotoxic T lymphocyte stimulants; Dendritic cell stimulants; Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Gastric cancer
- Phase II Colorectal cancer; Squamous cell cancer
- Phase I/II Acute myeloid leukaemia; HER2 positive breast cancer; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
- Phase I Breast cancer; Urogenital cancer
Most Recent Events
- 09 Apr 2024 Efficacy and adverse events data from the phase I/II trial in Non-Hodgkin's lymphoma
- 07 Mar 2024 ALX Oncology plans a registrational phase III trial for Gastric cancer in fourth quarter of 2024
- 04 Oct 2023 Effiacy and adverse events data from the phase II/III ASPEN-06 trial in Gastric cancer released by ALX Oncology